Cristiano Franzi

Cristiano Franzi is Senior Vice President & President Baxter EMEA.

Cristiano holds a bachelor’s degree in marketing from The American University, an MBA from George Washington University, and completed an executive education program at Harvard Business School.

His experience spans over 20 years in the international healthcare market with proven track record in both large multinational and new venture environments.

Prior to his current role, Cristiano served as President, Minimally Invasive Therapies Group, EMEA, for Medtronic following its acquisition of Covidien, where he had served as President, Europe, for Covidien. While at Covidien, Cristiano also held several leadership roles across a broad range of therapeutic areas, functions and European geographies. Prior to Covidien, Cristiano served in commercial positions at ev3, Boston Scientific/SciMed and Becton Dickinson.

This blog is part of the Early Diagnosis campaign #BeFirst Early diagnosis and care can prevent illness from developing and slow disease progression. Lab tests, genetic tests, tests for chronic diseases and modern lab diagnostics can help facilitate earlier intervention and improves outcomes for patients and are increasingly valuable in informing treatment choice. Read the other blogs here: A smarter way to fight colorectal cancer , Why should we prevent cervical cancer? Because we can , Diagnosing severe hearing loss and deafness , Can screening decrease lung cancer mortality rates? and Kidney Disease: catch it early to save lives and money . *************************************************** To me, modern healthcare should be about improving patient outcomes and offering patients as much choice as possible. All of us are patients at certain times in our lives. Shouldn’t we have greater input into how and where we are treated? When it comes to kidney disease, not all patients have time to consider their options and prepare for treatment. To understand why this is, let me explain a little about the condition. Kidney disease is a major and growing burden in Europe . One in ten Europeans has some form of kidney disease but most don’t know it . However, kidney failure is a ‘silent disease’, often diagnosed in the late stages. This significantly narrows the treatment options available to patients, often leading to worse outcomes. For some, late diagnosis denies them the opportunity to learn about and to discuss home dialysis with their doctors. Clinical guidelines – such as the NICE clinical guidance on peritoneal dialysis –recommend that stage 5 chronic kidney disease patients should be informed of all treatment options so that they can choose the one that best fits their lifestyle. Time to explore treatment options The best treatment for kidney failure is...